Nkgen Biotech Inc (NKGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -49,348 | -16,171 | -8,322 | -26,754 | -19,806 |
| Depreciation Amortization | 903 | 603 | 304 | 1,210 | 904 |
| Accounts receivable | 29 | 29 | 29 | -29 | -45 |
| Accounts payable and accrued liabilities | 2,100 | 298 | 436 | 443 | 91 |
| Other Working Capital | 809 | -176 | 216 | 30 | -325 |
| Other Operating Activity | 30,498 | 4,973 | 2,423 | 2,543 | 2,090 |
| Operating Cash Flow | $-15,009 | $-10,444 | $-4,914 | $-22,557 | $-17,091 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -30 | -30 | -13 | -163 | -158 |
| Investing Cash Flow | $-30 | $-30 | $-13 | $-163 | $-158 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 26,446 | 13,656 | 5,600 | 23,000 | 17,500 |
| Common Stock Issued | 11,889 | 12 | 4 | 161 | 160 |
| Other Financing Activity | -14,377 | -1,839 | -46 | -675 | -675 |
| Financing Cash Flow | $23,958 | $11,829 | $5,558 | $22,486 | $16,985 |
| Beginning Cash Position | 117 | 117 | 117 | 351 | 351 |
| End Cash Position | 9,036 | 1,472 | 748 | 117 | 87 |
| Net Cash Flow | $8,919 | $1,355 | $631 | $-234 | $-264 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,009 | -10,444 | -4,914 | -22,557 | -17,091 |
| Capital Expenditure | -30 | -30 | -13 | -163 | -158 |
| Free Cash Flow | -15,039 | -10,474 | -4,927 | -22,720 | -17,249 |